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Background I 
 
- Patient selection, perioperative care 
 
- Modified surgical techniques 
 
- Neoadjuvant treatment concepts 
 
have led to better outcomes in locally advanced 
   esophageal cancer during the last decades 
 
 
 
 
 
 
 
Background II 
 
However the effect of the extent of 
lymphadenectomy during surgery for esophageal 
cancer on outcomes is currently questioned. 
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Aim of the study 
 
 
To investigate the effect of the extent of removed    
lymph nodes on early reoperations and in-hospital 
mortality and morbidity in patients undergoing 
TME for esophageal cancer. 
 
Main focus on the last decade (16 years) 
Single center, retrospective study 
Prospective evaluation of patients since 2001  
Logistic regression analysis 
 
 
 
Outcome 
Primary Outcome:  
Early reoperations and in-hospital mortality 
 
Secondary Outcomes:  
Epidemiology and Tumor characteristics 
Perioperative complications  
Total number of Lymph nodes (Ln) and > or < 15 Ln 
Survival rate  
Surgical approach and nRCT 
 
  
 
 
 
Periode (10/01– present) 
 
Cancer cases treated with TME 
included 
n=314 
 
 
n= 247 
Systemic neoadjuvant treatment 
nRCT (T3+/N+) 
 
 
n= 189 
76.5 % 
 
 
Demographics and  
tumor characteristics  
   
 
 
 
Tumor site 
            Upper 0.5 % 
            Mid 12.2 % 
            Lower thoracic/AEG I 87.3 % 
Sex  (m/f) 77.2/ 22.8 % 
Age (y) 67 (IQR 14) 
ASA III 51.1% 
  Histology 
            Squamous cell 20.8% 
            Adenocarcinoma 74.3% 
            Other 4.4 %  
Clinical T stage 
          III-IV 60 % 
Clinical N stage 
          N+ 71.6%  
Resection 
          RO 96 % 
Resected lymph nodes (mean)      26 (2-82) 
Tumor characteristics 
   Mortality 
  In hospital 2.8 %  
1x Respiratory failure 
2x Heart failure 
1x ARDS  
1x Pneumonia, 1x MOF, 1x PE 
Reoperations 6.4%  
4x Lekage 
2x Haemtoma 
2x Cardiac tamponade,  
1x Perforation (colon) 
1x Bronchopulmonal fistula,  
2x Eviszeration, 2x Ileus, 1x 
Diaphragmatic hernia, 1x Pancreatitis 
 
Mortality + reoperations 
Morbidity 
2001-2017 
  
TME 
(n=247) 
Complications 
Pulmonal 24% 
ARDS 1.5% 
Anastomotic leak 12 % 
Hemorrhage 2.2% 
Wound infection 11.8% 
Recurrent Laryngeal 
Nerve Paralysis (trans.) 
4.5% 
Ln harvested and risk of reoperation 
(n=247)  
subgroup after nRCT (n=189) 
 
 
p=0.432 
p=0.281 
p=0.481 
p=0.240 
p=0.498 
p=0.481 
Ln harvested and risk of mortality 
(n=247)  
 subgroup after nRCT (n=189) 
 p=0.338 
p=0.819 
p=0.856 
p=0.833 
p=0.530 
p=0.494 
Ln harvested and risk of morbidity 
(n=247)  
subgroup after nRCT (n=189) 
p=0.881 
p=0.921 
p=0.872 
p=0.692 
p=0.858 
p=0.779 
Ln harvested and risk of morbidity 
(n=247)  
subgroup after nRCT (n=189) 
p=0.816 
p=0.663 
p=0.552 
p=0.767 
p=0.414 
p=0.652 
Overall survival 
Conclusion 
Extended lymphadenectomy is not 
associated with an increased rate of 
reoperations and in-hospital morbidity + 
mortality   
(incl. after neoadjuvant treatment) 
 
Extended lymphadenectomy in patients with 
TME can be regarded as a safe procedure  
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